ADME Profiling and In Silico Evaluation of Embelia ribes Phytochemicals as Human Lysyl Oxidase-Like 2 (hLOXL2) Inhibitors
DOI:
https://doi.org/10.48047/n7753a27Keywords:
.Abstract
Cancer and fibrotic disorders remain major global health challenges, prompting the search for novel therapeutic targets and safer drug candidates. Among the molecular targets implicated in disease progression, Lysyl Oxidase‑Like 2 (LOXL2) has emerged as an important enzyme involved in extracellular matrix remodeling and collagen cross-linking
Downloads
References
Sundaravadivazhagan B, Mohan S, Rengaraju B. Recent Developments in Microbiology, Biotechnology and Pharmaceutical Sciences. CRC Press; 2025. 1185 p.
Bocci V. Oxygen-Ozone Therapy: A Critical Evaluation. Springer Science & Business Media; 2002. 486 p.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
